A new combination of factor Xa inhibition and standard antiplatelet therapy to prevent more recurrent cardiovascular events in ACS

With an unrestricted educational grant from BAYER HEALTHCARE PHARMACEUTICALS

Learning Objectives

  • To understand the importance of the interplay between the coagulation cascade and platelets in arterial thrombus formation: thrombin generation remains high even after platelet hyperactivity retained to normal
  • To comprehend the rationale for oral antiplatelet and anticoagulant therapy to reduce residual thromboembolic risk for patients following ACS
  • To acknowledge the significant reduction of cardiovascular mortality and stent thrombosis in patients following ACS when combining rivaroxaban 2.5mg BID and standard antiplatelet therapy

Presentations available when logged in:

  • Translating survival benefit into clinical practice in patients following ACS: choosing the right patient
  • Thrombin generation and its critical role in ACS: combining anticoagulant and antiplatelet therapy in the acute phase and in secondary prevention o...
  • New era of anticoagulation: reducing mortality and preventing stent thrombosis in ACS patients when combining rivaroxaban 2.5mg BID and standard an...
  • Rivaroxaban: proven experience and new clinical activities
  • Introduction and objectives
  • Take-home message